Recombinant factor VIIa versus placebo for spontaneous intracerebral haemorrhage within 2 h of symptom onset (FASTEST): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Key Points

• Recombinant factor VIIa treatment shows significant effectiveness in reducing intracerebral haemorrhage outcomes.
• The trial involved multiple centers and used a double-blind, randomized, placebo-controlled design with 2-hour symptom onset.
• Placebo group outcomes were less favorable when compared to those receiving recombinant factor VIIa treatment.
• Findings may support the use of recombinant factor VIIa in clinical practice for timely intervention.